| Budget Amount *help |
¥19,110,000 (Direct Cost: ¥14,700,000、Indirect Cost: ¥4,410,000)
Fiscal Year 2013: ¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2012: ¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2011: ¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2010: ¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2009: ¥3,510,000 (Direct Cost: ¥2,700,000、Indirect Cost: ¥810,000)
|
|---|
| Research Abstract |
Avian influenza viruses such as H5N1 virus possess a pandemic potential. Possible emergence of drug-resistant viruses emphasizes the importance of influenza vaccines. However, low efficacy of the current inactivated vaccines and limited safety of the live attenuated vaccines provide a need for novel vaccine strategy against influenza. Here I generated replication-incompetent viruses, which infect cells once followed by expression of viral preventive antigens in animals, leading to a new vaccine with higher efficacy and safety. To this end, I produced replication-incompetent viruses such as M2-, NS2-, NA-, or HA-deletion construct by reverse genetics. These can replicate in each protein-expressed cell cultures, followed by intranasal inoculation into mice to evaluate their safety and vaccine efficacy. Conclusively replication-incompetent virus with defective HA fusion is promising as an alternative influenza vaccine.
|
